Our findings highlight the complex dynamics of the immune microenvironment in AML and emphasize how immune checkpoint molecules, especially TIGIT, contribute to immune exhaustion, while NKG2D appears to support favorable clinical outcomes through its expression on γδ T cells. Here, TIGIT is linked to acute myeloid leukemia.